Phase III randomized trial comparing intravenous to oral iron in patients with cancer‐related iron deficiency anemia not on erythropoiesis stimulating agents

Phase III randomized trial comparing intravenous to oral iron in patients with cancer‐related... 1INTRODUCTIONAnemia is common in patients with malignancy. Ludwig et al. performed a prospective survey in 15,367 European cancer patients, and found that at enrolment, the overall prevalence of anemia was 39.3% and patients who received chemotherapy had the highest incidence of anemia at 62.7%. Anemia in cancer patients is multifactorial; nutritional deficiencies (iron, vitamin B12 and folate) are important etiologies.Iron deficiency anemia is one of the commonest forms of nutritional anemia, characterized by inadequate iron stores. Iron deficiency can be a true or functional deficiency. The standard therapy for iron deficiency anemia is iron supplementation, most commonly by oral iron supplements. The established indications for parenteral, that is intravenous (IV) iron supplementation include failure of oral iron, intolerance to oral iron, a condition that confers refractoriness to oral iron (e.g., post‐gastrectomy, celiac disease, atrophic gastritis, H. pylori infection, etc.), need for rapid anemia reversal (e.g., late in pregnancy, chronic bleeding), with erythropoietin stimulating agents (ESA) in chronic renal failure patients and as a substitute for blood transfusions in persons who refuse blood products on religious grounds. In patients on cytotoxic chemotherapy, receiving ESA, who have concomitant iron deficiency or inadequate ESA response, iron supplementation is recommended. Several studies have shown http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Asia-Pacific Journal of Clinical Oncology Wiley

Phase III randomized trial comparing intravenous to oral iron in patients with cancer‐related iron deficiency anemia not on erythropoiesis stimulating agents

Loading next page...
 
/lp/wiley/phase-iii-randomized-trial-comparing-intravenous-to-oral-iron-in-wSIDzkiK0l
Publisher
Wiley Subscription Services, Inc., A Wiley Company
Copyright
Copyright © 2018 John Wiley & Sons Australia, Ltd
ISSN
1743-7555
eISSN
1743-7563
D.O.I.
10.1111/ajco.12762
Publisher site
See Article on Publisher Site

Abstract

1INTRODUCTIONAnemia is common in patients with malignancy. Ludwig et al. performed a prospective survey in 15,367 European cancer patients, and found that at enrolment, the overall prevalence of anemia was 39.3% and patients who received chemotherapy had the highest incidence of anemia at 62.7%. Anemia in cancer patients is multifactorial; nutritional deficiencies (iron, vitamin B12 and folate) are important etiologies.Iron deficiency anemia is one of the commonest forms of nutritional anemia, characterized by inadequate iron stores. Iron deficiency can be a true or functional deficiency. The standard therapy for iron deficiency anemia is iron supplementation, most commonly by oral iron supplements. The established indications for parenteral, that is intravenous (IV) iron supplementation include failure of oral iron, intolerance to oral iron, a condition that confers refractoriness to oral iron (e.g., post‐gastrectomy, celiac disease, atrophic gastritis, H. pylori infection, etc.), need for rapid anemia reversal (e.g., late in pregnancy, chronic bleeding), with erythropoietin stimulating agents (ESA) in chronic renal failure patients and as a substitute for blood transfusions in persons who refuse blood products on religious grounds. In patients on cytotoxic chemotherapy, receiving ESA, who have concomitant iron deficiency or inadequate ESA response, iron supplementation is recommended. Several studies have shown

Journal

Asia-Pacific Journal of Clinical OncologyWiley

Published: Jan 1, 2018

Keywords: ; ; ; ;

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial